Interventional Cardiology Journal
ISSN: 2471-8157

Open access Commentary

Advancements in Medical Technology: Drug-eluting Stents

Feng Xiang*

Department of Cardiology, Fudan University, China

DESCRIPTION

Medical technology has seen significant advancements in recent years, improving the treatment options available for various health conditions. One such innovation is the development of Drug-Eluting Stents (DES), which have revolutionized the field of interventional cardiology. These tiny, implantable devices have played a crucial role in the treatment of coronary artery disease, and their effectiveness in preventing restenosis has made them a preferred choice for many patients. In this article, we will explore the world of drug-eluting stents, how they work, and their impact on cardiovascular healthcare. Coronary Artery Disease (CAD) is a common heart condition that results from the gradual buildup of atherosclerotic plaques in the coronary arteries, leading to reduced blood flow to the heart muscle. This reduction in blood flow can cause chest pain, or angina, and in severe cases, may lead to heart attacks. To treat CAD, one common approach is Percutaneous Coronary Intervention (PCI), a procedure in which a stent is inserted to open narrowed or blocked arteries. In the past, Bare-Metal Stents (BMS) were the primary choice for PCI. BMS are simple metal scaffolds that are inserted into the narrowed coronary artery to keep it open. While they were effective in reducing the risk of acute vessel closure, they had a major limitation: They often led to restenosis, the re-narrowing of the artery due to excessive tissue growth. Restenosis occurred in a significant number of patients, requiring repeat interventions and posing a significant challenge to long-term treatment success. To address the restenosis problem, drug-eluting stents were introduced in the early 2000s. DES are coated with a special drug-releasing polymer that gradually releases an anti-proliferative drug over time. This drug inhibits the growth of cells in the arterial wall, reducing the risk of restenosis. The combination of a stent and drug therapy made DES a game-changer in the treatment of CAD, significantly improving patient outcomes. DES are inserted into the coronary artery in a similar manner to BMS. Once in place, the polymer coating on the stent begins to release the anti-proliferative drug. This drug interferes with the cell proliferation and migration, which are crucial processes in the development of restenosis. By controlling these cellular activities, DES effectively prevent excessive tissue growth, reducing the risk of narrowing the artery again. DES have been highly successful in reducing the occurrence of restenosis compared to BMS. This means that patients who receive DES are less likely to require repeat interventions. With a lower risk of restenosis, patients treated with DES experience better long-term outcomes, reduced chest pain, and a lower likelihood of subsequent heart attacks. The use of DES has resulted in fewer repeat PCI procedures, reducing healthcare costs and the burden on patients. Advances in DES technology allow for the customization of drug release profiles, ensuring optimal treatment for each patient's unique needs. While DES have revolutionized the treatment of CAD, they are not without their challenges. Patients must adhere to antiplatelet therapy for an extended period to prevent stent thrombosis, which is a rare but potentially life-threatening complication. Additionally, there is an ongoing need for research to optimize drug-eluting stent design and reduce the risk of late complications.

ACKNOWLEDGEMENT

None.

CONFLICT OF INTEREST

The author’s declared that they have no conflict of interest.

Received:	02-October-2023	**Manuscript No:**	IPIC-23-18330
Editor assigned:	04-October-2023	**PreQC No:**	IPIC-23-18330 (PQ)
Reviewed:	18-October-2023	**QC No:**	IPIC-23-18330
Revised:	23-October-2023	**Manuscript No:**	IPIC-23-18330 (R)
Published:	30-October-2023	**DOI:**	10.21767/2471-8157.9.10.93

Corresponding author Feng Xiang, Department of Cardiology, Fudan University, China, E-mail: fengfeng@123.com

Citation Xiang F (2023) Advancements in Medical Technology: Drug-eluting Stents. Interv Cardiol J. 9:93.